Urine Biomarkers for Bladder Cancer
Inventors: Bruce Zetter, Adam Feldman, Scott McDougal
Invention Types: Diagnostic/Prognostic
Research Areas: Oncology/Hematology, Urology
Keywords: BiomarkerFor More Information Contact: Dietz, Ryan
Bladder cancer is the second most common genitourinary cancer in the US. While 70% of new cases present as tumors without invasion into the muscularis propria, up to 50-70% of those cases will recur after resection and 10-20% will progress to a more invasive form of the disease. There remains a critical need to identify molecular markers that will allow for better prediction of which patients will recur and progress to metastatic disease.
Using proteomics and antibody-based approaches, Dr. Zetter and colleagues found elevated levels of cystatin B, a cathepsin protease inhibitor, in bladder cancer tissue as well as a correlation between urinary cystatin B levels and transitional cell carcinoma (TCC) grade/stage. Cathepsin proteases are known to be increased in various cancers and cystatin B protein levels have been demonstrated to correlate with tumor presence and stage in other cancers. Multivariate analysis that controlled for tumor grade, stage, multifocality, and subsequent BCG therapy confirmed that urinary cystatin B is a highly significant predictor of disease grade/stage progression in TCC.
Cystatin B is a clinically useful prognostic marker for bladder cancer.
• Cystatin B as a biomarker may improve the ability to predict which patients will develop invasive, metastatic disease and allow for more personalized treatments
• Compared to other clinicopathologic data, cystatin B is a highly significant predictor of early disease recurrence and progression
Collaboration and licensing opportunities available
Key Publications: Feldman et al., 2009. Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clinical Cancer Research 15(3): 1024-1031 | US patent #8,685,659 issued, EPO issued #1842065